Amgen Inc.
Method for preparing AMG 416

Last updated:

Abstract:

A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. It is being developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD).

Status:
Grant
Type:

Utility

Filling date:

3 Apr 2015

Issue date:

10 Sep 2019